Purpose: Tumors from 50% of epidermal growth factor receptor (EGFR) mutant non–small
cell lung cancer patients that develop resistance to gefitinib or erlotinib will contain a …

For patients with advanced non-small cell lung cancer (NSCLC), the introduction of the epi-
dermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib …

A secondary epidermal growth factor receptor (EGFR) mutation, the substitution of threonine
790 with methionine (T790M), leads to acquired resistance to reversible EGFR‐tyrosine …

Introduction Approximately 50% of lung cancer patients with epidermal growth factor
receptor (EGFR)-mutations (deletion in exon 19 or L858R) who develop acquired resistance …

Background: The epidermal growth factor receptor (EGFR) mutation T790M is reported in
approximately 50% of lung cancers with acquired resistance to EGFR inhibitors and is a …

Mutations in the epidermal growth factor receptor (EGFR) are observed in a fraction of non‐
small‐cell lung cancers (NSCLS). EGFR mutation‐positive NSCLS responds to gefitinib …

ABSTRACT Background EGFR T790M is the most common mutation associated with
acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). Baseline EGFR T790M …

Background Detection of epidermal growth factor receptor (EGFR) mutations in advanced
non-small cell lung cancer (NSCLC) patients has relied on DNA purification from biopsies …

Abstract Purpose: The T790M gatekeeper mutation in the EGFR is acquired by some EGFR-
mutant non–small cell lung cancers (NSCLC) as they become resistant to selective tyrosine …

EGFR is frequently mutated and amplified in lung adenocarcinomas sensitive to EGFR
inhibitors gefitinib and erlotinib. A secondary mutation, T790M, has been associated with …